https://www.selleckchem.com/pr....oducts/apo866-fk866.
It has been preclinically and clinically proven that anticancer agent-incorporating (ACA-incorporating) polymeric micelles selectively accumulate in tumor via the enhanced permeability and retention (EPR) effect, yielding a wider therapeutic window and greater safety than conventional low-molecular weight ACAs. To increase the antitumor effect of these safer micelle formulations, epirubicin-incorporating polymer micelles (NC-630 conjugated with monoclonal antibodies (mAbs) have been prepared. In this study, we used two types of m
Like
Comment
Share
